United Arab Emirates · Delayed Price · Currency is AED CTI BioPharma Statistics
Total Valuation
DFM:EKTTITAB has a market cap or net worth of AED 82.99 million. The enterprise value is 82.68 million.
| Market Cap | 82.99M |
| Enterprise Value | 82.68M |
Important Dates
The next estimated earnings date is Wednesday, August 13, 2025.
| Earnings Date | Aug 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 318.62M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.85% |
| Shares Change (QoQ) | -3.28% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7,121.44 |
| PB Ratio | 6.10 |
| P/TBV Ratio | 5.99 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -55.98 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.01
| Current Ratio | 0.01 |
| Quick Ratio | 0.01 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -9.87% and return on invested capital (ROIC) is -6.17%.
| Return on Equity (ROE) | -9.87% |
| Return on Assets (ROA) | -4.32% |
| Return on Invested Capital (ROIC) | -6.17% |
| Return on Capital Employed (ROCE) | -10.71% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +21.97% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +21.97% |
| 50-Day Moving Average | 0.20 |
| 200-Day Moving Average | 0.18 |
| Relative Strength Index (RSI) | 71.25 |
| Average Volume (20 Days) | 14,533,289 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, DFM:EKTTITAB had revenue of AED 11,654 and -1.48 million in losses. Loss per share was -0.00.
| Revenue | 11,654 |
| Gross Profit | 11,654 |
| Operating Income | -1.48M |
| Pretax Income | -1.48M |
| Net Income | -1.48M |
| EBITDA | n/a |
| EBIT | -1.48M |
| Loss Per Share | -0.00 |
Balance Sheet
The company has 55,771 in cash and n/a in debt, giving a net cash position of 55,771.
| Cash & Cash Equivalents | 55,771 |
| Total Debt | n/a |
| Net Cash | 55,771 |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 13.61M |
| Book Value Per Share | 0.04 |
| Working Capital | -6.60M |
Cash Flow
| Operating Cash Flow | -501,214 |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -12,674.01% |
| Pretax Margin | -12,674.01% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
DFM:EKTTITAB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.85% |
| Shareholder Yield | n/a |
| Earnings Yield | -1.78% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
DFM:EKTTITAB has an Altman Z-Score of -15.1 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -15.1 |
| Piotroski F-Score | 1 |